Ovid director receives RSU grant worth $22,500

Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.

Ovid Therapeutics Inc. reported that director Bart Friedman received a grant of 8,789 shares of Common Stock as a restricted stock unit (RSU) award, valued at $22,500 based on a reference price of $2.56 per share.

The RSU award was issued under Ovid’s Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer for Board service. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026, conditioned on his continuous service.

Insider Trade Summary

Grant/Award: 8,789 shares

Grant/Award 1 txn

Insider Friedman Bart

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,789	$2.56	$22K

Holdings After Transaction: Common Stock — 8,789 shares (Direct)

Footnotes (1)

1. F1. Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of 50% of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $22,500. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

RSUs granted: 8,789 shares Reference share price: $2.56 per share Aggregate award value: $22,500 +3 more

6 metrics

RSUs granted 8,789 shares Restricted stock unit award to director Bart Friedman

Reference share price $2.56 per share Value used for the Common Stock RSU award

Aggregate award value $22,500 50% of annual cash retainer replaced by RSUs

Initial vesting portion 25% RSUs vest 25% upon grant date

Subsequent vesting dates June 30, 2026; September 30, 2026; December 31, 2026 Three remaining 25% vesting tranches

Shares after transaction 8,789 shares Total Common Stock held directly following the grant

Key Terms

restricted stock unit ("RSU"), Non-Employee Director Compensation Policy, annual cash retainer, vest

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award issued to the Reporting Person"

Non-Employee Director Compensation Policy financial

"award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy"

annual cash retainer financial

"in lieu of 50% of an annual cash retainer for service on the Issuer's Board"

vest financial

"The RSUs vest 25% upon grant and 25% on each of June 30, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ovid Therapeutics (OVID) disclose in this Form 4?

Ovid Therapeutics reported a grant of 8,789 RSUs of Common Stock to director Bart Friedman. The award is valued at $22,500 and represents non-cash compensation under the company’s Non-Employee Director Compensation Policy for his Board service.

How many Ovid Therapeutics (OVID) shares were granted to director Bart Friedman?

Bart Friedman was granted 8,789 restricted stock units of Ovid Therapeutics Common Stock. These RSUs are issued as equity compensation in place of 50% of his $22,500 annual cash retainer for serving on the company’s Board of Directors.

What is the dollar value of the RSU award reported by Ovid Therapeutics (OVID)?

The RSU award to director Bart Friedman has an aggregate value of $22,500. This amount corresponds to 50% of his annual cash retainer for Board service, delivered in the form of restricted stock units instead of cash payments.

What reference price per share was used for the Ovid Therapeutics (OVID) RSU grant?

The RSU grant to Bart Friedman used a reference price of $2.56 per share of Ovid Therapeutics Common Stock. This price, multiplied by 8,789 RSUs, aligns with the $22,500 aggregate value disclosed for the director’s equity-based compensation.

How do the Ovid Therapeutics (OVID) RSUs granted to Bart Friedman vest over time?

The RSUs vest 25% on the grant date and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026. Each vesting installment requires Bart Friedman’s continuous service on Ovid’s Board of Directors through the respective vesting date.

Why did Ovid Therapeutics (OVID) issue RSUs instead of cash to its director?

Ovid issued RSUs to director Bart Friedman under its Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer. This structure shifts part of his Board compensation from cash payments into equity-based awards tied to Ovid’s Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 05:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friedman Bart

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		A(1)		8,789	A	$2.56	8,789	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of 50% of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $22,500. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Jeffrey Rona, Attorney-in-Fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)